3',4',5',3,5,6,7-HeptamethoxyflavoneCAS# 17245-30-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 17245-30-6 | SDF | Download SDF |
PubChem ID | 389001 | Appearance | Yellow cryst. |
Formula | C22H24O9 | M.Wt | 432.4 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 3,5,6,7-tetramethoxy-2-(3,4,5-trimethoxyphenyl)chromen-4-one | ||
SMILES | COC1=CC(=CC(=C1OC)OC)C2=C(C(=O)C3=C(C(=C(C=C3O2)OC)OC)OC)OC | ||
Standard InChIKey | SHRSLVWLFNSTLK-UHFFFAOYSA-N | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Targets | Antifection |
3',4',5',3,5,6,7-Heptamethoxyflavone Dilution Calculator
3',4',5',3,5,6,7-Heptamethoxyflavone Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3127 mL | 11.5634 mL | 23.1267 mL | 46.2535 mL | 57.8168 mL |
5 mM | 0.4625 mL | 2.3127 mL | 4.6253 mL | 9.2507 mL | 11.5634 mL |
10 mM | 0.2313 mL | 1.1563 mL | 2.3127 mL | 4.6253 mL | 5.7817 mL |
50 mM | 0.0463 mL | 0.2313 mL | 0.4625 mL | 0.9251 mL | 1.1563 mL |
100 mM | 0.0231 mL | 0.1156 mL | 0.2313 mL | 0.4625 mL | 0.5782 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Coumurrayin
Catalog No.:BCN1109
CAS No.:17245-25-9
- 2-(Hydroxymethyl)anthraquinone
Catalog No.:BCN3090
CAS No.:17241-59-7
- 2-Hydroxy-3-methylanthraquinone
Catalog No.:BCN1108
CAS No.:17241-40-6
- Dihydrodaidzein
Catalog No.:BCN2819
CAS No.:17238-05-0
- 2-Hydroxy-3-methoxybenzoic acid glucose ester
Catalog No.:BCN7407
CAS No.:172377-87-6
- Scabioside C
Catalog No.:BCC8358
CAS No.:17233-22-6
- PKC β pseudosubstrate
Catalog No.:BCC5811
CAS No.:172308-76-8
- Mepivacaine HCl
Catalog No.:BCC4796
CAS No.:1722-62-9
- Ilaprazole
Catalog No.:BCC9000
CAS No.:172152-36-2
- Gericudranin E
Catalog No.:BCN8070
CAS No.:172104-07-3
- Alpha-Tocotrienol
Catalog No.:BCN3724
CAS No.:1721-51-3
- H-Phe(4-NO2)-OMe.HCl
Catalog No.:BCC3294
CAS No.:17193-40-7
- 9-Deacetyl-9-benzoyl-10-debenzoyltaxchinin A
Catalog No.:BCN7671
CAS No.:172486-22-5
- Eupatarone
Catalog No.:BCN7199
CAS No.:17249-61-5
- Senkyunolide R
Catalog No.:BCC9144
CAS No.:172549-37-0
- Naringin 4'-glucoside
Catalog No.:BCN8196
CAS No.:17257-21-5
- Murrayamine E
Catalog No.:BCN7908
CAS No.:172617-68-4
- Eucalyptone
Catalog No.:BCN1111
CAS No.:172617-99-1
- Clemastanin A
Catalog No.:BCC8151
CAS No.:172670-47-2
- Fosaprepitant
Catalog No.:BCC4281
CAS No.:172673-20-0
- Fmoc-β-Homo-Val-OH
Catalog No.:BCC2626
CAS No.:172695-33-9
- Senkyunolide S
Catalog No.:BCC9145
CAS No.:172723-28-3
- Varespladib (LY315920)
Catalog No.:BCC2310
CAS No.:172732-68-2
- Mudanpioside C
Catalog No.:BCN2798
CAS No.:172760-03-1
DMC (2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone) improves glucose tolerance as a potent AMPK activator.[Pubmed:26975545]
Metabolism. 2016 Apr;65(4):533-42.
OBJECTIVE: We investigated the effect and regulatory mechanism of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone (DMC) isolated from Cleistocalyx operculatus on metabolic parameters in myotubes, adipocytes and an obese mouse model. MATERIALS AND METHODS: Myotubes and adipocytes were incubated with or without DMC. Glucose uptake, fatty acid oxidation, AMPK activation and adipocytes differentiation were investigated. To examine in vivo effect of DMC, 30mg/kg/day DMC was administered by oral gavage for 2weeks in high fat fed C57BL/6 male mice and intra-peritoneal glucose tolerance test was performed. In order to examine whether DMC directly activates AMPK, we performed cell free AMPK assay and surface plasmon resonance spectroscopy analysis. RESULT: DMC increases glucose uptake and fatty acid oxidation (FAO) in myotubes. Also, DMC inhibits adipocyte differentiation in 3T3-L1 cells. Interestingly, DMC stimulates phosphorylation of AMP-dependent protein kinase (AMPK) alpha subunit (T172) by directly binding to AMPK, which results in the activation of AMPK. Furthermore, DMC binds AMPK with a higher affinity than AMP. When AMPK was knocked down, the stimulatory effect of DMC on FAO and its inhibitory effect on adipogenesis were abolished. These results suggest that the effects of DMC were primarily mediated by AMPK activation. In addition, treating mice fed a high fat diet with DMC improved glucose tolerance and significantly increased FAO of the muscles. CONCLUSION: DMC, as a novel AMPK activator, shows anti-diabetic effects in cell culture systems, such as myotubes and adipocytes, and in a diet-induced obese mouse model.
Cytotoxic, Antiproliferative and Pro-Apoptotic Effects of 5-Hydroxyl-6,7,3',4',5'-Pentamethoxyflavone Isolated from Lantana ukambensis.[Pubmed:26690473]
Nutrients. 2015 Dec 10;7(12):10388-97.
Lantana ukambensis (Vatke) Verdc. is an African food and medicinal plant. Its red fruits are eaten and highly appreciated by the rural population. This plant was extensively used in African folk medicinal traditions to treat chronic wounds but also as anti-leishmanial or cytotoxic remedies, especially in Burkina Faso, Tanzania, Kenya, or Ethiopia. This study investigates the in vitro bioactivity of polymethoxyflavones extracted from a L. ukambensis as anti-proliferative and pro-apoptotic agents. We isolated two known polymethoxyflavones, 5,6,7,3',4',5'-hexamethoxyflavone (1) and 5-hydroxy-6,7,3',4',5'-pentamethoxyflavone (2) from the whole plant of L. ukambensis. Their chemical structures were determined by spectroscopic analysis and comparison with published data. These molecules were tested for the anti-proliferative, cytotoxic and pro-apoptotic effects on human cancer cells. Among them, 5-hydroxy-6,7,3',4',5'-pentamethoxyflavone (2) was selectively cytotoxic against monocytic lymphoma (U937), acute T cell leukemia (Jurkat), and chronic myelogenous leukemia (K562) cell lines, but not against peripheral blood mononuclear cells (PBMCs) from healthy donors, at all tested concentrations. Moreover, this compound exhibited significant anti-proliferative and pro-apoptotic effects against U937 acute myelogenous leukemia cells. This study highlights the anti-proliferative and pro-apoptotic effects of 5-hydroxy-6,7,3',4',5'-pentamethoxyflavone (2) and provides a scientific basis of traditional use of L. ukambensis.
Crystal structure of 2'-[(2',4'-di-fluoro-biphenyl-4-yl)carbon-yl]-1'-phenyl-1',2',5',6',7',7a'-hexa-h ydro-spiro-[indole-3,3'-pyrrolizin]-2(1H)-one.[Pubmed:26396754]
Acta Crystallogr E Crystallogr Commun. 2015 Jul 11;71(Pt 8):915-8.
In the title pyrrolizidine derivative, C33H26F2N2O2, both pyrrolidine rings of the pyrrolizidine moiety adopt an envelope conformation. The di-fluoro-phenyl group is oriented at an angle of 54.3 (1) degrees with respect to the oxindole moiety. The crystal packing features an N-Hcdots, three dots, centeredO hydrogen bond, which forms an R 2 (2)(8) motif, and a C-Hcdots, three dots, centeredO inter-action, which generates a C(8) chain along [010]. In addition, this chain structure is stabilized by C-Hcdots, three dots, centeredpi inter-actions. In one of the pyrrolidine rings, the methyl-ene group forming the flap of an envelope and the H atoms of the adjacent methyl-ene groups are disordered over two sets of sites, with site-occupancy factors of 0.571 (4) and 0.429 (4).
Discovery of 4-((3'R,4'S,5'R)-6''-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2''-oxodispiro[ cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamido)bicyclo[2.2.2]octane -1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development.[Pubmed:28339198]
J Med Chem. 2017 Apr 13;60(7):2819-2839.
We previously reported the design of spirooxindoles with two identical substituents at the carbon-2 of the pyrrolidine core as potent MDM2 inhibitors. In this paper we describe an extensive structure-activity relationship study of this class of MDM2 inhibitors, which led to the discovery of 60 (AA-115/APG-115). Compound 60 has a very high affinity to MDM2 (Ki < 1 nM), potent cellular activity, and an excellent oral pharmacokinetic profile. Compound 60 is capable of achieving complete and long-lasting tumor regression in vivo and is currently in phase I clinical trials for cancer treatment.